Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2024; 15(3): 565-567
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.565
Chiglitazar and Thiazolidinedione in patients with type 2 diabetes: Which is better?
Kotha Sugunakar Reddy, Archana Gaur, Sakthivadivel Varatharajan, Arvind Kumar Morya
Kotha Sugunakar Reddy, Department of General Medicine, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India
Archana Gaur, Department of Physiology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India
Sakthivadivel Varatharajan, Department of Medicine, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India
Arvind Kumar Morya, Department of Ophthalmology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India
Author contributions: Morya AK designed and formulated the research; Reddy KS, Gaur A and Varatharajan S performed the research; Reddy KS, Gaur A and Varatharajan S analyzed data and wrote the letter; and Morya AK revised the letter; all the authors have read and approved the final manuscript.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arvind Kumar Morya, MBBS, MNAMS, MS, Additional Professor, Department of Ophthalmology, All India Institute of Medical Sciences, Bibi Nagar, Hyderabad 508126, Telangana, India. bulbul.morya@gmail.com
Received: October 24, 2023
Peer-review started: October 24, 2023
First decision: December 19, 2023
Revised: December 19, 2023
Accepted: January 30, 2024
Article in press: January 30, 2024
Published online: March 15, 2024
Processing time: 133 Days and 20.4 Hours
Core Tip

Core Tip: The authors had done an indirect comparison between the new anti-diabetic drug Chiglitazar with Thiazolidinediones. It is premature to compare a single, relatively smaller study to 142 studies on Thiazolidinediones which are spanning over 28 years. Also, the efficacy of different thiazolidinediones has not been comprehensively compared and emphasized in the analysis and discussion.